medigraphic.com
ISSN 0185-6014 (Impreso)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2002, Número 1

<< Anterior Siguiente >>

Rev Mex Patol Clin Med Lab 2002; 49 (1)


Enfermedades reumáticas y embarazo: manifestaciones clínicas y cambios inmunológicos y moleculares

Cuéllar-Dávila JA, Reyes-Jaime AM, Muñoz-Valle JF, Vázquez-Del Mercado M

Idioma: Español
Referencias bibliográficas: 38
Paginas: 15-22
Archivo PDF: 76.38 Kb.


RESUMEN

Las enfermedades reumáticas forman un conjunto de patologías en las que intervienen múltiples factores, endocrinos, inmunológicos y moleculares y se caracterizan por deterioro progresivo de los pacientes. Por otro lado, el embarazo es un evento en donde existe modificación transitoria del sistema inmunitario y endocrino, con predominio de la inmunidad humoral y producción de anticuerpos sobre la inmunidad mediada por células. Esto nos da una base para explicar los cambios clínicos en artritis reumatoide y lupus eritematoso sistémico (que son las enfermedades reumáticas más comunes y representativas) y también nos da idea de las modificaciones moleculares que se presentan en este evento reproductivo. Por una parte existe mejoría clínica evidente de las mujeres embarazadas que cursan con artritis reumatoide y por otra se presenta exacerbación, de carácter variable, en el caso del lupus eritematoso sistémico. En este artículo discutimos los aspectos inmunológicos, hormonales y moleculares que se presentan en el embarazo normal y en aquellos que cursan con artritis reumatoide o lupus eritematoso sistémico, tratando de esclarecer la fisiología y fisiopatología molecular del fenómeno embarazo-enfermedades reumáticas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Michelle P. Rheumatic Disease Clinics of North America. Pregnancy and Rheumatic Disease. 1997.

  2. Alfonse TM. Seminars in arthritis and rheumatics. Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. 1995; 25(1): 1-27.

  3. Ostensen. Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Annals of the New York Academy of Sciences. 1999; 876: 131-134.

  4. McCune WJ. Rheumatic Disease Clinics of North America. 1994.

  5. Vigano A. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clinical and Experimental Immunology 1996; 106(1): 127-133.

  6. Wilder R. Hormonal regulation of tumor necrosis factor-[alpha], interleukin-12 and interleukin-10. Production by activated macrophages: A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erithematosus? Annals of the New York Academy of Sciences. 1999; 876: 14-31.

  7. Puppo F. Determination of soluble HLA-G and HLA-A, -B, and -C molecules in pregnancy. Transplantation Proceedings 1999; 31: 1841-1843.

  8. Athanassakis. Detection of soluble HLA-G levels in maternal serum can be predictive for a successful pregnancy. Transplantation Proceedings 1999; 31: 1834-1837.

  9. Emmer PM. Natural killer cell reactivity and HLA-G in recurrent spontaneous abortion.

  10. Clemens LE. Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. Journal of Immunology 1979: 1978-1985.

  11. Hui L. Synthesis of T helper 2-Type cytokines at the maternal-fetal interface. Journal of Immunology 1993: 574-580.

  12. Athanassakis I. The immunostimulatory effect of T cells and T cells lymphokines on murine fetally derived. Placental Cells 1987; 13 8(1): 37-44.

  13. Mendonca LLF. Natural immune response involving anti-endothelial cell antibodies in normal and lupus pregnancy. Arthritis and Rheumatism 2000; 43(7): 1511-1515.

  14. Kruse N. Variations in cytokine mRNA expression during normal human pregnancy. Clinical and Experimental Immunology 2000; 119(2): 317-322.

  15. Athanassakis I. The immunostimulating effects of T cells and T cell lymphokines on murine fetally derived placental cells. Journal of Immunology 1999; 138(37): 125-130.

  16. Armstrong DT. Effects of lymphokines and immune complexes on murine placental cell growth in vitro. 1999; 40: 466.

  17. Robertson SA. Uterine epithelial cells synthesize granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-6 (IL-6) in pregnant and non pregnant mice. 1992; 46: 1069.

  18. Hill JA. T-helper 1-Type immunity to trophoblast in woman with recurrent spontaneous abortion. JAMA 1995; 273(24): 1933-1936.

  19. Wegmann TG. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? Immunology Today 1993; 14(7): 136-139.

  20. Hench PS. The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrositis, and intermittent hydrarthrosis. Mayo Clinic Procedures 1938; 13: 161-167.

  21. Perselin RH. The interaction of pregnancy and the rheumatic diseases. Clinical and Rheumatology Diseases 1981; 7: 747-768.

  22. Zvaifler NJ. The immunopathology of joint inflammation rheumatoid arthritis. Advances in Immunology 1973; 16: 265-283.

  23. Yoshinoya S. Detection and partial characterization of immune complexes in patients with rheumatoid arthritis plus Sjogren’s syndrome and with Sjogren’s syndrome alone. Clin Exp Immunol 1982; 2: 208-211.

  24. Unger. Disease activity and pregnancy associated (alpha) 2-glycoprotein in rheumatoid arthritis during pregnancy. Br Med J 1983; 286: 750-752.

  25. Persellin RH, Wiginton D, Rutstein J. Pregnancy alpha-glycoprotein (PAG) and rheumatoid arthritis (RA) activity: a prospective analysis during gestation. Arthritis Rheum 1982; 25: 6-21.

  26. Ostensen MB, Von Shoultz GH. Comparison between serum (alpha) 2-pregnancy-associated globulin and activity of rheumatoid arthritis and ankylosing spondylitis during pregnancy. Scand J Rheumatol 1983; 12: 315-318.

  27. Wilder R. Hormones, pregnancy and autoimmune diseases [Neuroimmunomodulation: molecular aspects, integrative systems, and clinical advances: new perspectives in neuroimmunomodulation] Ann N Y Acad Sci 1998; 840(1): 45-50.

  28. Khamashta MA. Systemic lupus erythematosus flares during pregnancy. Pregnancy and rheumatic disease. Rheumatic Disease Clinics of North America 1997.

  29. Siegel MS, Lee L. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum 1973; 3: 1-54.

  30. Lima F. Obstetric outcome in systemic lupus erythematosus. Semin Arthritis Rheum 1999; 25: 184-192.

  31. Buyon JP. Neonatal lupus: bedside to bench and back. Scand J Rheumatol 1996; 25: 271-276.

  32. Petri M. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 1997; 40: 797-803.

  33. Lahita RG. The effect of sex hormones on the immune system in pregnancy. Am J Reprod Immunol 1992; 28: 136-137.

  34. Cutolo M, Sulli A, Barole A. Sex hormones, proto-oncogene expression ad apoptosis: their effects on rheumatoid synovial tissue. Clin Exp Rheumatol 1996; 14: 87-94.

  35. Evans MJ, MacLauglilin S, Marvin RD. Estrogen decreases in vitro apoptosis of peripheral blood mononuclear cells from women with normal menstrual cycles and decreases TNF-alpha production in SLE but not in normal cultures. Clin Immunol Immunopathol 1997; 82: 258-262.

  36. Jara-Quezada L, Graef A, Lavalle C. Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol 1991; 18: 349-353.

  37. Petri M, Chan D. Longitudinal analysis of prolactin and disease activity in SLE pregnancy. Arthritis Rheum 1995; 38(Suppl.): S220.

  38. McMurray RW, Keisler D, Izui SS, Walker SE. Effects of parturation, suckling and pseudopregnancy on variables of disease activity in the BW mouse model of systemic lupus erythematosus. J Rheumatol 1993; 20: 1143-1151.




2020     |     www.medigraphic.com